Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials

被引：0
|
作者：
Saroj Niraula
Bishal Gyawali
机构：
[1] University of Manitoba and CancerCare Manitoba,Section of Medical Oncology and Hematology, Department of Internal Medicine
[2] Harvard Medical School,Department of Medicine, Brigham and Women’s Hospital
来源：
Breast Cancer Research and Treatment | 2019年 / 173卷
关键词：
Breast cancer; Herceptin; Duration; Adjuvant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：103 / 109
页数：6
相关论文
共 50 条
  • [1] Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials
    Niraula, Saroj
    Gyawali, Bishal
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (01) : 103 - 109
  • [2] Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials
    Dahabreh, Issa J.
    Linardou, Helen
    Siannis, Fotios
    Fountzilas, George
    Murray, Samuel
    ONCOLOGIST, 2008, 13 (06): : 620 - 630
  • [3] Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
    Yin, Wenjin
    Jiang, Yiwei
    Shen, Zhenzhou
    Shao, Zhimin
    Lu, Jinsong
    PLOS ONE, 2011, 6 (06):
  • [4] Efficacy and safety of shorter duration of adjuvant trastuzumab for patients with HER2 positive early breast cancer: A meta-analysis of randomized controlled trials
    Li, J.
    Wang, G.
    Wu, Q.
    Chen, C.
    Tu, Y.
    Yao, F.
    Wei, W.
    Sun, S.
    Santa-Maria, C. A.
    Geng, P.
    CANCER RESEARCH, 2019, 79 (04)
  • [5] Extended duration of adjuvant aromatase inhibitor in breast cancer: a meta-analysis of randomized controlled trials
    Clement, Zackariah
    Kollias, James
    Bingham, Janne
    Whitfield, Robert
    Bochner, Melissa
    GLAND SURGERY, 2018, 7 (05) : 449 - 457
  • [6] Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
    Gustavo A Viani
    Sergio L Afonso
    Eduardo J Stefano
    Ligia I De Fendi
    Francisco V Soares
    BMC Cancer, 7
  • [7] Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials
    Viani, Gustavo A.
    Afonso, Sergio L.
    Stefano, Eduardo J.
    De Fendi, Ligia I.
    Soares, Francisco V.
    BMC CANCER, 2007, 7 (1)
  • [8] Adjuvant Denosumab treatment in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials
    Mastrantoni, Luca
    Garufi, Giovanna
    Di Monte, Elena
    Maliziola, Noemi
    Pasqualoni, Mariangela
    Pontolillo, Letizia
    Pannunzio, Sergio
    Cannizzaro, Maria Chiara
    Di Bello, Armando
    Fabi, Alessandra
    Palazzo, Antonella
    Bria, Emilio
    Tortora, Giampaolo
    Orlandi, Armando
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Hypofractionated Radiotherapy as Adjuvant Treatment in Early Breast Cancer. A Review and Meta-Analysis of Randomized Controlled Trials
    Budach, Wilfried
    Bolke, Edwin
    Matuschek, Christiane
    BREAST CARE, 2015, 10 (04) : 240 - 245
  • [10] Additional adjuvant capecitabine in early breast cancer patients: a meta-analysis of randomized controlled trials
    Zhou, Wenqi
    Cao, Yong
    Gou, Ping
    Zeng, Xiaohua
    Hu, Xiaolei
    Lin, Zhousheng
    Ye, Changsheng
    Chen, Lujia
    Yao, Guangyu
    FUTURE ONCOLOGY, 2021, 17 (35) : 4993 - 5002
12345